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Abstract
Background: Vaccines are the most effective agents to control infections. However, recombinant vaccines often do
not elicit strong immune responses. Protein antigens combined with proper adjuvants have been widely used to
induce immune responses, especially the humoral immune responses, against various pathogens, including
parasites. The extracellular matrix protein mindin has been recognised as an immune facilitator for initiating innate
immune responses. It has therefore been expected to be a potentially potent adjuvant in the development of novel
vaccines. The aim of this study was to investigate whether mindin could facilitate the induction of antigen-specific
immune responses to recombinant antigens (rBAG1, rSRS4 and rSRS9) of Toxoplasma gondii in BALB/c mice.
Methods: In this study, we explored the adjuvant effect of the recombinant mindin in the generation of specific
Th1 and Th2 responses to each of three T. gondii antigens, BAG1, SRS4 and SRS9. All mice in the experimental groups
received either antigen alone or in combination with Freund’s adjuvant or with the recombinant mindin. The immune
responses after immunisation were measured by ELISA and lymphoproliferative assays. The immunised mice were
challenged with live T. gondii tachyzoites, and the protection efficiency was compared between the groups.
Results: Our results revealed that mindin as an adjuvant could facilitate the recombinant proteins to efficiently
stimulate humoral and cellular responses, including antigen-specific IgG1 and IgG2a, as well as lymphocyte proliferation.
Furthermore, significantly improved protection against T. gondii infection was observed in the mindin group compared
with that of Freund’s adjuvant and no-adjuvant groups.
Conclusions: The extracellular matrix protein mindin can effectively induce antigen-specific humoral and cell-mediated
immune responses. Our study provides a valuable basis for the development of an efficient, safe, non-toxic vaccine
adjuvant for future use in humans and animals.
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Background
Vaccine adjuvants facilitate the production of long-lasting,
efficient and specific immune responses and improve the
protective effect of vaccines due to a higher antibody yield
and the persistence of antibodies, as well as functional T
cells at high levels. Currently, the most common adjuvant
used in experimental animals is Freund’s adjuvants, which
can enhance strong antigen-specific immune responses.
However, it causes strong inflammation and necrosis at
the injection site, which prevents its use in vaccine
development. Aluminium-derived adjuvants are often
used in clinical trials and have the reputation of safety and
the facilitation of long-lasting antibody responses [1],
but the effect on cell-mediated immunity remains
questionable when used along with small immunogenic
antigens. To develop safe and effective adjuvants for
enhancing both humoral and cellular immune responses,
we focused on the selection of novel immunofacilitators
based on their roles in initiating innate and adaptive
immune responses.
Mindin (also known as spondin 2) belongs to the
mindin-F-spondin family of secreted extracellular matrix
(ECM) proteins that includes mammalian F-spodin,
zebrafish mindin 1 and 2, and Drosophila M-spondin
[2-5]. Mindin has been known to essentially initiate
innate immunity and serve as a bridge between innate
and adaptive immunity [6]. Previous reports indicated
that mindin-deficient mice had an impaired capability
to clear influenza virus and bacterial infection, and
mindin-deficient macrophages exhibit defective responses
to a broad spectrum of microbial stimuli. This is because
mindin is a pattern recognition molecule and can directly
bind to sugar moieties in bacterial cell walls [7] and
influenza virus particles to initiate innate immune
responses, as well as function as an opsonin for
macrophage phagocytosis of bacteria [8]. Interestingly,
even recombinant mindin alone is capable of promoting
viral clearance in wild-type mice [6]. Possible mechanisms
for mindin’s effects on immunity system include binding
to a cell surface receptor, activating synergistic signal
transduction pathways for proinflammatory cytokine
production, interacting with other pattern recognition
receptors (PRR) (such as the Toll-like receptors) and
enhancing their recognition of bacterial products,
inducing bacterial phagocytosis to enhance the immune
response to infection, or a combination of these
mechanisms [7]. Based on these findings, mindin has
been considered as a novel vaccine adjuvant candidate
in view of its superior immune-enhancing capabilities.
Toxoplasma gondii, a member of the Apicomplexa
phylum, is an obligatory intracellular and opportunistic
parasite that infects both warm-blooded animals and
human beings to cause toxoplasmosis [9]. This parasite
is a highly prevalent, zoonotic pathogen of medical,
veterinary and economic importance [10,11]. Acquired
toxoplasmosis is usually an asymptomatic disease of
adults, which most likely persists for the lifetime of the
hosts. However, this disease can be quite severe or even
fatal for immunocompromised patients, such as those
with AIDS, organ transplant recipients, or those with
neoplastic diseases [12,13], and the sequelae associated
with diseases include blinding chorioretinitis, lymphaden-
opathy, encephalitis and/or death [14]. Toxoplasmosis has
long been a disease of worldwide importance for public
health and economic development. Consequently, the
development of an effective vaccine for controlling the
impact of this disease is urgently needed.
Currently, the best developed vaccine is the live,
attenuated tachyzoite S48 [15], which has not been
widely applied because of its high cost, side effects, and
short shelf life. More importantly, attenuated vaccines
carry a risk of unexpected harmful reverse mutations
and accidental infections of humans [16]. To overcome
these issues, most of current research has been focused
on searching for subunit or recombinant vaccines. The
SAG1-related sequence (SRS) super-family, encoding
glycophosphatidylinositol (GPI)-anchored surface proteins
[17], are the crucial surface antigens of T. gondii that
participate in the process of host cell attachment and
regulate the virulence of these parasites, which could be a
promising vaccine candidate against toxoplasmosis [18].
Furthermore, the SRS9 molecule, a bradyzoite-specific
SRS antigen, has been suggested to be an important target
of the host immune response in the mouse intestine [19].
SRS4 has been shown to be able to elicit strong antibody
responses in humans infected by T. gondii and has been
considered as a diagnostic and/or vaccine antigen
[20,21]. In addition, BAG1, a T. gondii 30-kDa cytosolic
heat-shock protein, preferentially expressed at the brady-
zoite stage, is very immunogenic because of its induction
of early humoral and cell-mediated immune responses
upon infection in humans [22-24]. Therefore, we chose
BAG1, SRS4 and SRS9 of T. gondii as vaccine candidates
to assess the immune-enhancing effect of mindin. The
function of mindin as a novel adjuvant for the T. gondii
antigens BAG1, SRS4 and SRS9 was evaluated through an
analysis of the induction of antigen-specific antibodies,
lymphocyte proliferation and the immune protection
capacity in challenge experiments. The results showed
that the extracellular matrix protein mindin is a very
potent adjuvant molecule owing to its enhancement of
both humoral and cell-mediated immune responses.
Methods
Animals and parasites
Female BALB/c and male Kunming strain outbred mice
aged 8 to 10 weeks were used in all experiments.
Kunming mice were used to maintain and passage
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T. gondii tachyzoites, whereas BALB/c mice were used
in the immunisation experiments. The permission to
work with laboratory animals was obtained from the
Ethical Committee of the Institute of Zoonosis, Jilin
University, China (Permission number 2008-IZ-20).
Tachyzoites of the RH strain of T. gondii were harvested
from the peritoneal fluid of Kunming mice after intraperi-
toneal infection.
Generation of recombinant proteins
The Mus musculus spon 2 gene-encoding extracellular
matrix protein mindin was chemically synthesised with
restriction sites (BamHI and HindIII) at the 5′ and 3′
ends, respectively. The gene fragment was subcloned into
the plasmid pET-22b (Qiagen, Düsseldorf, Germany) to
construct an expression plasmid, which was subsequently
confirmed by enzymatic digestion and sequencing. After
transformation of the plasmid into BL21 (DE3) competent
cells, the expression of the His-tag fusion protein was
induced by the addition of IPTG at 37°C for 5 h. The
recombinant protein in inclusion bodies was purified by
Ni-affinity chromatography (GE Healthsystems, Uppsala,
Sweden) according to the manufacturer’s instructions.
The inclusion bodies were solubilised by 6 M urea, and
the purified, denatured mindin was refolded by dialysis in
PBS containing urea (initial concentration was 6 M,
then decreased by 1 M/dialysis) and 0.5 M arginine.
Subsequently, the refolded protein was dialysed 5
times against the dialysis buffer to remove arginine
changing from 0.5 M-0 M buffers, 12 h/time-point.
Finally, the protein was confirmed by SDS-PAGE and
Western blotting.
The recombinant T. gondii antigens (rBAG1, rSRS4
and rSRS9) were generated as described in our previous
study [25].
Immunisation schedule and serum collection
Animals were immunised with one of the three
recombinant antigens (rBAG1, rSRS4 and rSRS9) formu-
lated with complete Freund’s adjuvant (CFA)/incomplete
Freund’s adjuvant (IFA) (Sigma–Aldrich, St. Louis,
MO, USA), the recombinant protein mindin or PBS.
To formulate the Freund’s adjuvant emulsion, the
antigens were mixed with an equal volume of adjuvant
solution in two syringes connected with an adaptor
(Sigma). Each test group contained eleven mice and the
control groups with the same number of animals receiving
the CFA/IFA, mindin or PBS alone, respectively.
All mice were immunised intramuscularly with the
antigen-adjuvant mixtures on weeks 2, 4, 6 and 8. The
amount of each recombinant antigen used for each
immunisation was 20 μg/mouse. Serum samples were
collected from all animals in each group prior to the first
immunisation and 10 days after each immunisation. Sera
were separated from blood by centrifugation at 2000 rpm
for 15 min and stored at −80°C until further analysis.
Detection of specific antibody responses by ELISA
IgG levels in the collected sera were determined by an
enzyme-linked immunosorbent assay (ELISA). Maxisor
micro-ELISA plates (Nalge Nunc International, IL, USA)
were coated with 50 μl per well of the T. gondii recom-
binant antigens (rBAG1, rSRS4 and rSRS9, respectively)
in a concentration of 5 μg/ml at 4°C overnight. The
plates were washed four times with PBS containing
0.05% Tween 20 and blocked for 1 h at 37°C with 100 μl
per well of 3% bovine serum albumin (BSA) in coating
buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6). The
sera of immunised mice diluted from 1:1000 to 1:128,000
were added in triplicate and allowed to incubate for 1 h at
37°C. Plates were washed, and bound IgG was detected by
incubation for 1 h with alkaline phosphatase-conjugated
goat anti-mouse IgG (1:20,000, Sigma). Finally, 50 μl of
pNPP [4-Nitrophenyl phosphate disodium salt hexahy-
drate] (Sigma, St. Louis, USA) and 9.7% diethanolamine
(pH 9.8) were used to detect antigen-antibody reactions.
The optical density (OD) was read at 405 nm in a Biotek
micro-ELISA auto-reader 808 (Bio-TEK Instruments,
Winooski, USA).
For typing the IgG subclasses, the three fusion
proteins were each coated on ELISA plates as described
previously and incubated with sera (1:1000) from immu-
nised mice. Antigen-specific IgG subclasses were there-
after identified with commercial kits (BioLegend San
Diego, CA, USA) according to the protocols provided by
the manufacturer.
Lymphocyte proliferation assays
Three mice from each group were euthanised two weeks
after the last immunisation. Their spleens were removed
under sterile conditions. Single-cell suspensions were
obtained by filtration through a 200-mesh copper grid.
After separation with mouse Percoll (Sigma) used
according to the manufacturer’s instructions, the remaining
splenocyte suspensions were diluted to a final concentra-
tion of 5 × 106 cells/ml in RPMI 1640 with 10% foetal
bovine serum (Sigma). Splenocyte suspensions (100 μl/well)
were plated into 96-well cell culture plates. The cells were
stimulated with 20 μg/ml rBAG1, rSRS4 and rSRS9 at 37°C
for 60–72 h in the presence of 5% CO2 followed by the
addition of 10 μl/well MTT solutions (5 mg/ml). The
plates were then incubated for 4 h at 37°C followed
by an addition of 150 μl/well DMSO solution. The
sample absorbance at 570 nm was then measured.
Concanavalin A (10 μg/ml, Sigma) was used as a
positive control, and cells cultured with media alone
were used as negative controls. The growth index was
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calculated according to the formula, Growth Index
(GI) = (ODtest-ODnegative)/(ODpositive)-ODnegative).
Challenge infection
Eight mice in each group were challenged intraperitoneally
with 250 tachyzoites of T. gondii RH strain/mouse 2 weeks
after the last immunisation. The mice were carefully
observed for 20 days.
Statistical analysis
GraphPad Prism 5 (GraphPad InStatt Software, San
Diego, California) and one-factor analysis of variance
(ANOVA) were used in this study. Data are expressed as
the mean ± standard deviation (SD). The differences be-
tween groups were considered to be significant when the P
value was less than 0.05. The Kaplan-Meier survival curves
were generated with the MedCalc statistical software
(http://www.medcalc.org/manual/kaplan-meier.php).
Results and discussion
The expression and purification of the recombinant
extracellular matrix protein mindin
The recombinant mindin and rBAG1, rSRS4 and rSRS9
were purified by Ni-affinity chromatography and analysed
by SDS-PAGE and Western blotting. The recombinant pro-
teins appeared predominantly as single bands (Figure 1),
which were sufficiently pure for the subsequent experiment.
Humoral immune responses are induced by vaccination
with antigens combined with different adjuvants
In order to evaluate both the immunogenicity and
adjuvant effect of recombinant mindin, BALB/c mice
were immunised with rBAG1, rSRS4 and rSRS9 in
combination with different adjuvants (Freund’s adjuvant
and mindin) or recombinant antigens alone, and antigen-
specific IgG antibodies were measured by ELISA. The vac-
cination of mice with recombinant antigens formulated
with Freund’s adjuvant or the mindin adjuvant induced
significantly higher levels of IgG than found with antigens
alone (p < 0.05; Figure 2). Mindin, therefore, had an
adjuvant potency and could significantly increase the
antigenicity of the T. gondii proteins.
Because the antibody subclass is a measurement of the
relative contribution of Th2- versus Th1- type immune
responses, we further analysed the IgG subtypes to
assess the type of the humoral immunity induced by the
different antigen-adjuvant combinations. In mice, the
production of IgG1 versus IgG2a is widely interpreted as
a reflection of Th2- or Th1 reactivity [26,27]. In this
study, ratios of IgG1/IgG2a levels in sera collected from
immunised mice were calculated after the final immun-
isation. We determined that the levels of IgG1 and
IgG2a from BALB/c mice immunised with antigens in
combination with Freund’s adjuvant or the mindin
adjuvant were clearly higher than those from mice
immunised with recombinant antigens alone after the
last immunisation (Figure 3). BALB/c mice immunised
with the antigens in combination with mindin generated
a mixed Th1/Th2 response with similar levels of IgG1
and IgG2a, whereas mice immunised with Freund’s
adjuvant generated a pro-Th1-type response, as revealed
by a lower IgG1/IgG2a ratio. Immunisation with protein
alone induced predominantly IgG1 in BALB/c mice,
suggesting a Th2-biased immune response. Thus, it
Figure 1 Purified and confirmation of recombinant proteins. His-tagged mindin, rBAG1, rSRS4 and rSRS9 fusion proteins were purified, and
the quality of the recombinant proteins was determined by a Coomassie-stained SDS-PAGE gel (lane 1 in A, B, C and D) and Western blot
(lane 2 in A, B, C and D). M lane is the protein marker.
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appears that mindin could facilitate the generation of
relatively balanced responses by the hosts. This result
may be more significant for protection against acute
toxoplasmosis. During the initial phase of T. gondii
infection, the parasites proliferate quickly without host
immune pressure. With the development of host
immune responses, the parasites can be inhibited by
both Th1 and Th2 responses. It is well known that
antigen-specific IgGs can block the T. gondii techyzoite
invasion of host cells and intracellular development
[28-30], whereas TNF-α and IFN-γ are important factors
in the suppression of parasite proliferation, especially by
constraining the dormant form of bradyzoites [31,32].
Thus, balanced responses would be able to produce
optimal immunoprotection [33].
The cellular immune responses of a splenocyte
proliferation assay in vitro
The splenocytes from immunised mice of different
groups were prepared 2 weeks after the last immunisation
to assess splenocyte proliferation in vitro (Figure 4).
After priming, marked specific lymphoproliferation was
observed in splenocyte cultures from mice immunised
with recombinant antigens combined with Freund’s
adjuvant and mindin adjuvant when stimulated with
rBAG1, rSRS4 or rSRS9 (p < 0.05) (Figure 4). This
proliferation was further increased when stimulated
with Concanavalin A as a positive control. In con-
trast, splenocytes from mice immunised with antigens
alone showed very weak responses when stimulated
with any of the three recombinant antigens. A suc-
cessful vaccine should trigger both humoral and cellu-
lar immune responses after immunisation. Our data
suggested that splenocytes from mice immunised with
rSRS9 formulated with mindin proliferated more
efficiently than those from mice immunised with Freund’s
adjuvants. Though immunisation with rBAG1 and
rSRS4 elicited significantly higher Th1 responses than
the medium control group, but the responses were
not as significant as that of the group immunised
with the rSRS9 antigen (Figure 4). The data further
supported the previous report that immunisation with
SRS antigen can elicit an antigen-specific Th1 response
marked by elevated IFN-γ production [34]. Thus,
rSRS9 along with the mindin adjuvant may be an
ideal vaccine combination and may induce both
humoral and cellular immune responses simultaneously
with high efficiency.
Figure 2 Antigen-specific IgG responses in different immunised mice after the final immunisation. BALB/c mice were immunised with
rBAG1 (A), rSRS4 (B), or rSRS9 (C) in combination with Freund’s adjuvant (black) or mindin adjuvant (red) or as proteins alone (blue). The IgG
response was detected on week 9 (2 weeks after final immunisation). IgG levels are presented as optical density (OD) values at 405 nm with sera
diluted from 1:1000 to 1:128,000. The statistical differences between the Freunds’ and the Mindin groups were significant in groups immunised
with rBAG1 and rSRS9 (A and C), but not in the groups immunised with rSRS4 (C).
Figure 3 IgG subclasses in the sera of immunised mice. The IgG subclass responses to recombinant antigens were detected after the last
immunisation. The values shown for each group are the mean ± SD of the antibody levels. (A): IgG subclass responses of rBAG1 antigen group;
(B): IgG subclass responses of rSRS4 antigen group; (C): IgG subclass responses of rSRS9 antigen group.
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T. gondii antigens combined with mindin elicited
protective immunity against a lethal challenge in
BALB/c mice
To evaluate the immuno-protection effect to T. gondii
infection induced by immunisation of the antigens com-
bined with different T. gondii antigens, the immunised
mice were challenged intraperitoneally (i.p.) with 250
tachyzoites of T. gondii RH strain 2 weeks after the last
immunisation, and mortality was monitored daily. The
survival rate of the various groups is shown in Figure 5.
The data revealed that effective and significant pro-
tection was obtained in the mice immunised with
recombinant antigens combined with Freund’s adju-
vant and mindin adjuvant, respectively. Mice immu-
nised with either antigen alone or adjuvant alone did
not show any resistance to the challenge, and all died
within 6 days after challenge (P > 0.05). The reason
that immunisation with the antigens did not provide
immunity against lethal challenge may be due to the
less expression of the antigens in the parasites. The
two antigens, BAG1 and SRS9 were predominantly
expressed at the bradyzoite stage of the parasite and
the immunised mice were challenged with tachyzoites.
These results, however, demonstrated that mindin as
an adjuvant can elicit similar immune-stimulating
effects as that of Freund’s adjuvant. Considering the
fact that fewer, if any, side effects were produced,
mindin could be a promising vaccine adjuvant worthy
of further investigation.
Conclusions
This study has proven that the extracellular matrix
protein mindin acts as a potent vaccine adjuvant, which
could enhance both humoral and cellular immune
responses against Toxoplasma infection. The precise mech-
anism by which mindin promotes immune responses,
however, remains open to further investigation.
Figure 4 Lymphocyte proliferation responses of immunised mice. All groups were intramuscularly immunised four times, and after priming,
antigen-stimulated spleen lymphocytes were prepared from three mice per group 2 weeks after the last immunisation, and their subsequent
proliferation responses were analysed and expressed as stimulation index (SI) values. Results are presented as the mean of SI values ± SD.
(A): Stimulation of rBAG1 antigen; (B): Stimulation of rSRS4 antigen; (C): Stimulation of rSRS9 antigen. The statistical difference between different
groups was considered to be significant when the P value was less than 0.05 (* means P < 0.05, ** means P < 0.01 and *** means P <0.001).
Figure 5 Survival of immunised mice after a lethal tachyzoite challenge. Groups of mice were intraperitoneally immunised with the
recombinant antigens in combination with the Freund’s adjuvant (light blue), mindin adjuvant (green), PBS (yellow), or Freund’s adjuvant alone (pink),
mindin adjuvant alone (black), and PBS alone (grey). Nine weeks after the immunisation, all experimental mice were intraperitoneally infected with 250
live tachyzoites of T. gondii (RH strain). Animals were observed daily for 20 days, and the final survival rates were recorded. (A): Mouse group immunised
with rBAG1 antigen and controls; (B): Mouse group immunised with rSRS4 antigen and controls; (C): Mouse group immunised with rSRS9 antigen and
controls. Mice immunised with the recombinant proteins in combination with either Freund’s adjuvant or mindin showed most prolonged survival time.
The Kaplan-Meier survival curves were generated with the MedCalc statistical software (http://www.medcalc.org/manual/kaplan-meier.php).
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